Avsnitt
-
Join Drs. Rahul & Rohit Gosain in this insightful episode of the Oncology Brothers podcast as they continue their treatment algorithm series, focusing on the rapidly evolving landscape of bladder cancer. They are joined by Dr. Joaquim Bellmunt, a medical oncologist and director of bladder cancer at the Dana-Farber Cancer Institute, who shares his expertise on the latest treatment paradigms for both muscle invasive and non-muscle invasive bladder cancer.
In this episode, you'll learn about:• The distinction between muscle invasive and non-muscle invasive bladder cancer and their respective treatment approaches.• The role of BCG treatment and emerging options for BCG-refractory disease.• The significance of the NIAGARA trial and its implications for neoadjuvant chemotherapy and perioperative immunotherapy.• Current strategies for managing muscle invasive bladder cancer, including the use of cisplatin-based therapies and the introduction of immunotherapy.• Insights into the metastatic space, including the use of enfortumab vedotin (EV) and pembrolizumab, and the importance of next-generation sequencing (NGS) in treatment decisions.• Key side effects to monitor with various treatments and the importance of maintaining quality of life for patients.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information.
YouTube: https://youtu.be/apUp2-BkgWQ
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/ Don't forget to like, share, and subscribe for more discussions on cancer treatment algorithms!
-
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Anwaar Saeed, Chief of GI Medical Oncology at UPMC, to discuss the recent approval of Tislelizumab, a new checkpoint inhibitor for upper GI malignancies, including esophageal squamous cell cancer, GE junction, and gastric cancer.
We dive deep into the studies that led to Tislelizumab’s approval, including the Rationale 302, 305, and 306 trials. Dr. Saeed explains the unique mechanism of action of Tislelizumab, its higher binding affinity to PD-1, and how it compares to other PD-1 inhibitors like nivolumab and pembrolizumab.
Key topics covered in this episode:• Overview of Tislelizumab and its mechanism of action• Insights from the Rationale 306 trial and its implications for frontline treatment• Discussion on the Rationale 305 trial focusing on adenocarcinoma• The importance of PD-L1 testing and biomarker-driven treatment decisions• Side effect profiles of Tislelizumab compared to other immunotherapies• Future directions in the use of immunotherapy for upper GI malignancies
Join us for this informative discussion that highlights the evolving landscape of cancer treatment and the importance of precision oncology. If you find this episode helpful, please share it with your colleagues and leave us a review!
YouTube: https://youtu.be/hQeLdpSzGCk
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to subscribe for more practice-changing discussions in the world of oncology. We are the Oncology Brothers!
-
Saknas det avsnitt?
-
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a leading GU medical oncologist from Dana-Farber Cancer Institute. Together, they dive into the highlights from the GU ASCO 2025 conference, covering key studies and updates in the world of genitourinary oncology.
Episode Highlights:• TALAPRO-2: An in-depth discussion on the role of PARP inhibitors in prostate cancer, focusing on the study's design, findings, and the importance of germline and NGS testing.• NIAGARA Update: Insights into the new standard of care for resectable muscle-invasive bladder cancer and the promising results from the perioperative approach with Durvalumab.• CheckMate-9ER Update: A look at the combination of Cabozantinib and Nivolumab in first-line metastatic RCC, including the latest findings and implications for treatment beyond the first line.• TiNivo2: Exploring the role of Tivozanib in the treatment landscape of RCC and potential sequencing strategies.
Join us for this informative discussion that aims to keep community oncologists up to date with the latest advancements in cancer care. If you find this episode helpful, please share it with your colleagues and leave us a review!
YouTube: https://youtu.be/OzeHhyAdF9Q
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights and updates from the Oncology Brothers!
-
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at the Winship Cancer Institute of Emory University.
Join us as we dive deep into the complexities of hormone receptor-positive breast cancer treatment. We discuss the latest advancements in treatment algorithms, including the use of OncotypeDX in premenopausal versus postmenopausal women, the role of ovarian function suppression, and the implications of new approvals like Inavolisib and CDK4-6 inhibitors.
Key topics covered in this episode:• The significance of recurrence scores in dictating adjuvant chemotherapy• The ongoing OFSET trial and its potential impact on treatment decisions• Insights into the use of genomic assays like MammaPrint and RS-Clin• The evolving landscape of treatment options for locally advanced and metastatic breast cancer• The latest on PARP inhibitors, T-DXd, and other novel therapies
Whether you're a medical professional or someone interested in the latest in oncology, this episode is packed with valuable insights and clinical pearls. Don't forget to subscribe for more discussions on cancer treatment, FDA approvals, and conference highlights!
YouTube: https://youtu.be/_icBN3J3Bc0
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
#OncologyBrothers #HR+ #breastcancer #HormoneReceptorPositiveCancer #oncbrothers #Podcast
-
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the recent advancements in the treatment of gastroesophageal junction (GEJ) and gastric cancer, focusing on the newly approved drug Zolbetuximab. They are joined by Dr. Kohei Shitara, the lead author of the pivotal SPOTLIGHT study, who shared insights on the mechanism of action of Zolbetuximab, its clinical trial findings, and the implications for patient care.
Key topics discussed include:• The mechanism of action of Zolbetuximab and its target, Claudin 18.2.• An overview of the GLOW and SPOTLIGHT studies, including study design and key findings on progression-free survival (PFS) and overall survival (OS).• Practical considerations for administering Zolbetuximab in clinical practice, including dosing schedules and side effect management.• The importance of testing for Claudin 18.2 and the challenges faced in rural settings without in-house testing.• Future directions in the treatment landscape for gastric cancer, including potential combination therapies and emerging agents.
Join us for this informative discussion that highlights the changing standard of care in gastric cancer treatment and the exciting possibilities ahead for patients.
Don't forget to like, share, and subscribe for more insightful conversations in the world of oncology!
YouTube: https://youtu.be/BfpDHpqgHMs
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
-
In this episode of the Oncology Brothers podcast, Drs. Rohit and Rahul Gosain welcome Dr. Sarah Sammons from Dana-Farber Cancer Institute to discuss the treatment landscape for HER2-positive breast cancer. Building on their previous discussions about triple-negative breast cancer, Drs. Gosain and Sammons dive deep into the treatment algorithms for early-stage, locally advanced, and metastatic HER2-positive breast cancer.
Key topics include:• Treatment paradigms for early-stage HER2-positive breast cancer, including the APT trial and considerations for neoadjuvant therapy.• The standard of care for locally advanced disease with TCHP and managing associated toxicities.• Insights into the latest data from the PATINA trial and its implications for metastatic HER2-positive patients.• Discussion on the use of T-DXd and other treatment options in the second and third-line settings, especially for patients with brain metastases.
Join us for an informative conversation filled with clinical pearls and practical insights that can help guide treatment decisions in HER2-positive breast cancer. Don't forget to like, subscribe, and check out our other episodes in the treatment algorithm series!#OncologyBrothers #HER2Positive #BreastCancer #BreastCancerTreatment #CancerPodcast #DanaFarber
YouTube: https://youtu.be/_y0xSxJTptw
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Virginia Kaklamani from the UTHealth San Antonio MD Anderson Cancer Center to discuss the latest advances in the treatment of triple negative breast cancer (TNBC) as we kick off 2025.
• The treatment paradigms for early-stage TNBC, including the role Sacituzumab and radiation therapy.• Insights from the SABCS 2024 conference, focusing on the keynote 522 regimen and its implications for neoadjuvant treatment.• The management of locally advanced and metastatic TNBC, including the use of immunotherapy and the importance of PD-L1 testing.• Strategies for managing toxicities associated with treatments like sacituzumab and T-DXd.
Whether you're a healthcare professional or someone interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!Key Takeaways:• Current standard of care for locally advanced TNBC.• The significance of chemotherapy and immunotherapy in treatment plans.• Managing toxicities in metastatic disease.Stay tuned for more discussions on treatment algorithms, FDA approvals, and clinical pearls in oncology!
YouTube: https://youtu.be/GfROoYPVb_8
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
-
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Alok Khorana, a GI medical oncologist from the Cleveland Clinic, to discuss the latest highlights from the GI ASCO 2025 conference.
We dive into four key studies that are practice-informing and potentially practice-changing:1. BREAKWATER: We explore the implications of using Encorafenib and Cetuximab in combination with FOLFOX for patients with BRAF V600E mutations, which are associated with poor prognosis.2. CheckMate-8HW: This study investigates whether dual checkpoint inhibition is more effective than single-agent immunotherapy for MSI-high patients, revealing promising results in progression-free survival.3. Aspirin in Adjuvant Settings: We discuss the role of low-dose aspirin in reducing recurrence rates for patients with PI3K alterations, highlighting its potential as a practice-changing intervention.4. STARTER-NET: Finally, we review the findings from the study on Everolimus combined with Lanreotide for neuroendocrine tumors, noting the lack of overall survival benefit.
Tune in for an insightful discussion on these important topics in oncology, and learn how these findings could impact treatment strategies in your practice. Don't forget to like, subscribe, and check out our other episodes for more conference highlights and treatment discussions!
YouTube: https://youtu.be/YOToz3hKYTg
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
#OncologyBrothers #GIASCO2025 #ColorectalCancer #Immunotherapy #NeuroendocrineTumors #CancerResearch #Podcast
-
Welcome to the Oncology Brothers Podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Saby George from Roswell Park Comprehensive Cancer Center to discuss the recent approval of subcutaneous nivolumab based on the CheckMate-67T study.Join us as we delve into:• The study design and findings of CheckMate-67T• The implications of subcutaneous nivolumab for patients and healthcare providers• Safety signals and side effects associated with the new formulation• The significant time savings for patients receiving treatment• Real-world experiences from patients involved in the trial
This episode highlights how the subcutaneous formulation of nivolumab can enhance patient care by reducing time spent in infusion centers while maintaining efficacy and safety.
Tune in to learn more about this exciting advancement in cancer treatment and its potential impact on patient quality of life! Don't forget to like, subscribe, and check out our other episodes for more insights on FDA drug approvals, conference highlights, and treatment algorithms. We are the Oncology Brothers!
YouTube: https://youtu.be/4blP8jqizUQ
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
Subscribe to our channel for more insights on oncology treatments and patient care!
-
In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC.
The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.
Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist), and Ed Kim (interventional radiologist) join the Oncology Brothers to share their insights on:
• Current treatment options for intermediate HCC, addressing its heterogeneity and standard treatment pathways
• Latest clinical trial data (EMERALD-1, LEAP-012) on combining IO with loco-regional therapies, and the clinical implications
• The importance of effective collaboration within the multidisciplinary team for delivering optimal patient care
• Combining IO with loco-regional therapy and future perspectives in the field
Clinical takeaways
• IO and IO-based treatments are moving earlier in the treatment paradigm for patients with intermediate HCC. Earlier integration of these therapies aims to achieve improved systemic control, allowing loco-regional therapy to target oligoprogression, residual lesions or reduce tumour burden
• Emerging data supports combining systemic and loco-regional therapies for patients with intermediate HCC. EMERALD-1 and LEAP-012 show promising PFS data using IO-based combination regimens like durvalumab + bevacizumab or pembrolizumab + lenvatinib alongside TACE. Long-term OS data are awaited
• Effective communication and coordinated care among specialists, such as medical oncologists, radiation oncologists, hepatologists, and interventional radiologists, are essential to developing optimal treatment strategies for patients with intermediate HCC
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• YouTube: https://www.youtube.com/channel/UCjfxKlVho5xWH5ltufj4F4A/
Subscribe to our channel for more insights on oncology treatments and patient care!
-
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Pashtoon Kasi from City of Hope to discuss the management of side effects associated with key treatments utilized in colorectal cancer, but also in other tumor types.
We dived deep into two important drug classes: Bevacizumab, an anti-VEGF antibody, and the anti-EGFR antibodies, Panitumumab and Cetuximab. Dr. Kasi provided a comprehensive overview of these targeted therapies, their mechanisms of action, and the common side effects that patients may experience.
Key topics covered in this episode included:• Overview of Bevacizumab and its side effects, including hypertension, proteinuria, and risk of bleeding.• Clinical pearls for managing side effects associated with Bevacizumab.• Discussion on the skin toxicities, nail changes, and electrolyte imbalances related to Panitumumab and Cetuximab.• The importance of preemptive strategies in managing skin rashes and other side effects.• Insights into infusion reactions with Cetuximab and considerations for patient safety.
Join us for this informative discussion that aims to enhance your understanding of these critical therapies and improve patient outcomes.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
Don't forget to check out our other episodes in the Tox Check series, where we explore antibody-drug conjugates and CAR T therapies.Subscribe to our channel for more insights on oncology treatments and patient care!
-
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the latest highlights from ASH 2024, focusing on key studies in lymphoma.
In this episode, we dive into:• POLARIX Study: An update on the POLARIX trial, exploring the use of Polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL) and its impact on progression-free survival (PFS).• inMIND Study: A look at the promising results of the inMIND study, which evaluates the combination of Tafasitamab with Lenalidomide and Rituximab in the second-line setting for follicular lymphoma.• Triangle Study: Insights into the evolving role of transplant in mantle cell lymphoma and the implications of BTK inhibitors in treatment.• ENRICH Study: Discussion on the potential of Ibrutinib combined with Rituximab in the first-line setting and its comparison to traditional chemoimmunotherapy.
Join us as we unpack these practice-changing studies, discuss their implications for clinical practice, and share insights on managing side effects associated with new therapies.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice!#OncologyBrothers #ASH2024 #Lymphoma #CancerResearch #Podcast
-
Join us for another insightful episode of the Oncology Brothers podcast as we dive into the latest breakthroughs in breast cancer research from the San Antonio Breast Cancer Symposium 2024. In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Sara Tolaney from Dana-Farber Cancer Institute to discuss three pivotal studies:
1. DESTINY-Breast06 - An update on the efficacy of T-DXd in HER2 low and ultra-low breast cancer patients, highlighting its potential to change treatment paradigms for endocrine refractory disease.2. DESTINY-Breast12 - Exploring the robust intracranial activity of T-DXd in patients with brain metastases and its impact on quality of life.3. PATINA Trial - A groundbreaking study on the use of CDK4-6 inhibitors in combination with trastuzumab and pertuzumab for ER-positive, HER2-positive breast cancer, showcasing impressive progression-free survival rates.
Tune in as we unpack the implications of these studies for clinical practice and discuss the future of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates on oncology research and treatment strategies!
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
For more information, visit our website: OncologyBrothers.com
#OncologyBrothers #BreastCancer #SABCS2024 #TDXD #PATINA #CancerResearch #Podcast
-
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Jame Abraham from the Cleveland Clinic to discuss key abstracts in the hormone receptor-positive breast cancer space from the San Antonio Breast Cancer Symposium 2024.
Episode Highlights:• EUROPA Trial: A phase 3 study comparing endocrine therapy versus radiation therapy in early-stage breast cancer patients over 70. Discover how the results may impact clinical practice and patient decision-making.• TAILORx Study: Updates on the benefits of anthracycline-based chemotherapy for patients with a recurrence score of 31 and above. Learn how this data influences treatment options for younger patients.• PADMA Study: Insights into the role of CDK4/6 inhibitors combined with endocrine therapy versus chemotherapy in aggressive disease settings. Understand why this combination remains the standard of care.• EMBER-3 Study: An exploration of the new oral selective estrogen receptor degrader, imlunestrant, and its promising results in combination with abemaciclib for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
Join us as we delve into these important studies and their implications for the future of breast cancer treatment. Don't forget to check out our other conference highlights from ASH 2024 and SABCS 2024!
Subscribe for more insights and updates in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In the third of this 4-part podcast series on hepatocellular carcinoma (HCC), the Oncology Brothers, Drs. Rahul and Dr Rohit Gosain, are joined by hepatologist Dr. Maria Reig and interventional radiologist Dr. Emil Cohen to explore treatment strategies for patients with intermediate-stage HCC.
The experts share valuable insights into the available treatment options for this heterogeneous patient group and explore the role of systemic treatments and multimodal approaches in achieving optimal patient outcomes.
The conversation dives deep into real-world clinical challenges in managing patients with intermediate HCC, including treatment sequencing and strategies based on the experts' experience in clinical practice and the available data. The speakers also highlight variations in practice across different centres and geographic regions.
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul & Rohit Gosain are joined by Dr. Laura Huppert from UCSF to discuss key highlights from the San Antonio Breast Cancer Symposium 2024.
We dive into three crucial studies:1. INSEMA Study: Explore the findings on the potential omission of axillary surgery in early-stage hormone receptor-positive breast cancer and its implications for patient quality of life.2. KEYNOTE-522 Update: Learn about the latest insights on the use of Pembrolizumab in triple-negative breast cancer, including the search for predictive biomarkers and the impact of achieving pathological complete response (PCR).3. OlympiA Study Update: Discover the updated results on the use of Olaparib in BRCA-positive patients, highlighting its significant benefits in invasive disease-free survival and overall survival.
Join us as we unpack these important studies and their implications for clinical practice. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Robert Orlowski from MD Anderson Cancer Center to discuss groundbreaking studies presented at ASH 2024 focused on multiple myeloma.
We dived into four key studies:1. AQUILA: Explore the impact of early intervention using daratumumab for smoldering myeloma, which showed improved progression-free survival (PFS) and overall survival (OS).2. Dara Based Quad Therapy: We discuss a meta-analysis reaffirming the use of quadruplet therapy with anti-CD38 for newly diagnosed multiple myeloma as the standard of care.3. CARTITUDE-4: study highlights the benefits of CAR-T therapy in earlier lines of treatment for patients with lenalidomide-refractory disease.4. Role of IVIG with BCMA Bispecific Antibodies: Discover how IVIG can reduce infection rates and improve overall survival when used alongside BCMA-targeted therapies.
Tune in for an insightful discussion that will enhance your understanding of the latest advancements in multiple myeloma treatment. Don't forget to check out our other episodes on CLL, myeloma, and lymphoma from ASH 2024!
Subscribe to the Oncology Brothers for more updates and expert insights in oncology!
Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at [email protected]
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of Zanidatamab, a bispecific HER2 antibody, for HER2 amplified, unresectable, locally advanced, or metastatic biliary tract cancer.Join us as we discuss the HERIZON-BTC-01 study with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center and one of the study's authors. We explore the significance of HER2 testing in biliary tract cancers, the study's design, key findings, and the implications for treatment strategies in the community oncology setting.
Key topics include:• Overview of biliary tract cancer and its treatment landscape• Study design and patient characteristics from the HERIZON-BTC-01 trial• Key findings, including overall response rates and duration of response• The importance of HER2 testing and its implications for treatment sequencing• Side effect profiles and management strategies for Zanidatamab• Future directions and ongoing clinical trials
Don't miss this insightful discussion that highlights the exciting advancements in HER2-targeted therapies for biliary tract cancer.Make sure to subscribe for more updates on recent FDA approvals, treatment algorithms, and conference highlights. We look forward to seeing you at GI ASCO 2025 in person!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. John Allan from New York Presbyterian Hospital to discuss the latest highlights from ASH 2024, focusing on Chronic Lymphocytic Leukemia (CLL).
We dived into three key studies:1. SEQUOIA Update: Discover how this study led to the approval of Zanubrutinib in the frontline setting and its impressive progression-free survival rates compared to traditional chemotherapy.2. AMPLIFY Study: Learn about the exciting combination of Acalabrutinib with Venetoclax and Obinutuzumab, and how it may pave the way for the first oral doublet/triplet combination approval in the U.S.3. Ongoing Trials: We touch on the CELESTIAL TN-CLL trial and the promising combination of Zanubrutinib with Sonrotoclax, a new BCL-2 inhibitor.
Additionally, we discuss the evolving role of CAR-T therapy in CLL, especially for patients who have progressed through multiple lines of treatment.
Join us for an insightful discussion on the future of CLL treatment options, the importance of balancing efficacy and side effects, and the exciting developments in the field. Don't forget to check out our other ASH and SABCS 2024 discussions!
Subscribe to stay updated on the latest in oncology research and treatments!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the rapidly evolving world of CAR T cell therapy, a groundbreaking treatment for various hematologic malignancies. Joined by experts Dr. Surbhi Sidana from Stanford University and Dr. Jason Westin from MD Anderson Cancer Center, we explore the mechanism of action of CAR T cells, their side effects, and management strategies.
Episode Highlights:
Understanding CAR T cell therapy and its application in hematologic malignancies and solid tumors.Mechanism of action: How CAR T cells are engineered to target cancer cells.Acute side effects: Cytokine release syndrome (CRS) and neurotoxicity, including clinical pearls for management.Chronic side effects: Monitoring for infections, cytopenias, and the risk of secondary malignancies.The importance of bridging therapy and managing tumor burden before CAR T treatment.Insights for community oncologists on patient management and communication with CAR T centers.Join us for an informative discussion that emphasizes the importance of recognizing and managing the unique side effects of CAR T therapy to ensure the best outcomes for patients. Don't forget to check out our other episodes for more insights into recent advances in hematology and oncology!
Subscribe for more discussions on FDA approvals, treatment algorithms, and conference highlights. We are the Oncology Brothers!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
- Visa fler
